Biosimilars Market | Growth, Trends, and Forecast (2019-2024)

Market Snapshot

Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

In the recent years, several blockbuster biologic drugs of major pharmaceuticals companies, such as Remicade, Rituxan, Herceptin, Enbrel, Lantus, and others expired. In the coming decade, there would be a rise in the patent expiration of several existing biological drugs, such as Erbitux, Avastin, Orencia, and others, which would provide an opportunity for many innovator companies as well as generic manufacturers to offer services, specially tailored toward biosimilars. In addition, factors, such as cost effectiveness nature of biosimilars, rising acceptance and adoption by various stakeholders with the need of diversification in technology and business models, growing prevelence of chronic diseases are expected to drive the global biosimilar market. At the same time, with factors, such as lack of definitive standards for approval and adequate profitability, given the greater risk with concerns regarding substitutability and interchangeability, many companies are discouraged from investing in this market, thus impeding the growth of the market studied.

Scope of the Report

A biosimilar is a biologic that is “similar” to another biologic medicine (known as a reference product) which is already licensed by the U.S. Food and Drug Administration (FDA). Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. In approving biosimilars, the FDA may require that manufacturers conduct a clinical study (or studies) sufficient to establish safety, purity or potency in one or more uses for which the reference product is licensed and the biosimilar seeks licensure.

Product Class
		Monoclonal Antibodies
		Recombinant Hormones
		Immunomodulators
		Anti-inflammatory Agents
		Others

Applications
		Blood disorders
		Growth hormonal deficiency
		Chronic and autoimmune disorders
		Oncology
		Others

Geography

North America
	US
	Canada
	Mexico

Europe
	Germany
	UK
	France
	Italy
	Spain
	Rest of Europe

Asia Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle East and Africa
	GCC
	South Africa
	Rest of Middle East and Africa

South America
	Brazil
	Argentina
	Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oncology segment holds the major share in global bio similar market

Applications segment of the market is segmented as Blood disorders, Growth hormonal deficiency, Chronic and autoimmune disorders, Oncology, Others. The oncology segment is dominating the global market for biosimilars in terms of revenue owing to the high prevalence of cancer including lung, liver, colorectal, stomach, breast, and blood cancer. According to the National Cancer Institute (NCI) report, it was estimated that 1,735,350 new cases of cancer are diagnosed in the US in 2018, and 609,640 people will die from the disease. Amelita, Amgen’s version of Humira is the first adalimumab biosimilar to be approved by the US FDA in September 2016. Two European versions, named Amgevita and Solymbic, were recommended in the European Union (EU) in January 2017.

To understand key trends, Download Sample Report

North America to dominate the growth of biosimilar market

North America accounted for the largest share, accounting for approximately 30% of the global market, in 2017. The North American segment of the market studied is majorly driven by the presence of many large research laboratories, such as Sandoz, Amgen, Teva Pharmaceutical, and others. According to a recent report, more than 40 biosimilars are under development, including approximately 20 biosimilars ready to be released into the market, and a significant number of biosimilars are in the pipeline. Owing to the immense economic developments and booming biotechnology companies in the region, Asia-Pacific is also expected to record robust growth over the forecast period. Furthermore, factors such as high demand for the low-cost therapeutics and treatments, high prevelance and incidence of various chronic diseases, increase in R&D expenditures by the market players in the emerging economies such as India, South Korea and China are also propelling the growth of biosimilars market in Asia Pacific region.

To understand geography trends, Download Sample Report

Competitive Landscape

There is massive competition in the Biosimilar market. With the presence of many domestic and also international market players. Most of the market players are adopting various growth strategies such as acquisitions, partnerships, new product launches to survive in the market. For instance,

In, 2018 Mylan NV launched Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets in Europe.
In October 2018, Sandoz, a Novartis division in biosimilars, recieved US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for treatment of rheumatoid arthritis, juvenile idiopathic arthritis in patients four years of age and older.
In Nov 2018, Teva recieved FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications

Major Players

* Complete list of players covered available in the table of contents below

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Several Blockbuster Biopharmaceuticals Going Off-Patent over the Next Five to Ten Years
  2. 4.2.2 Market in the Nascent Phase but with High Growth Potential
  3. 4.2.3 Increasing Demand for Biosimilar Drugs due to Their Cost Effectiveness
3. 4.3 Market Restraints
  1. 4.3.1 Concerns Regarding Substitutability and Interchangeability
  2. 4.3.2 Regulatory Uncertainty
  3. 4.3.3 Production Complexity
4. 4.4 Porter's Five Force Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 Product Class
  1. 5.1.1 Monoclonal Antibodies
  2. 5.1.2 Recombinant Hormones
  3. 5.1.3 Immunomodulators
  4. 5.1.4 Anti-inflammatory Agents
  5. 5.1.5 Others
2. 5.2 Applications
  1. 5.2.1 Blood disorders
  2. 5.2.2 Growth hormonal deficiency
  3. 5.2.3 Chronic and autoimmune disorders
  4. 5.2.4 Oncology
  5. 5.2.5 Others
3. 5.3 Geography
  1. 5.3.1 North America
    1. 5.3.1.1 US
    2. 5.3.1.2 Canada
    3. 5.3.1.3 Mexico
  2. 5.3.2 Europe
    1. 5.3.2.1 Germany
    2. 5.3.2.2 UK
    3. 5.3.2.3 France
    4. 5.3.2.4 Italy
    5. 5.3.2.5 Spain
    6. 5.3.2.6 Rest of Europe
  3. 5.3.3 Asia Pacific
    1. 5.3.3.1 China
    2. 5.3.3.2 Japan
    3. 5.3.3.3 India
    4. 5.3.3.4 Australia
    5. 5.3.3.5 South Korea
    6. 5.3.3.6 Rest of Asia-Pacific
  4. 5.3.4 Middle East and Africa
    1. 5.3.4.1 GCC
    2. 5.3.4.2 South Africa
    3. 5.3.4.3 Rest of Middle East and Africa
  5. 5.3.5 South America
    1. 5.3.5.1 Brazil
    2. 5.3.5.2 Argentina
    3. 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Pfizer Inc.
  2. 6.1.2 Eli Lilly and Company
  3. 6.1.3 Celltrion Healthcare
  4. 6.1.4 Mylan NV
  5. 6.1.5 Novartis AG
  6. 6.1.6 Samsung Bioepis Co. Ltd
  7. 6.1.7 Stada Arzneimittel AG
  8. 6.1.8 Teva Pharmaceutical Industries Ltd
  9. 6.1.9 Intas Pharmaceuticals Ltd
  10. 6.1.10 LG Life Sciences
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments